Detail akcie DexCom online

Business Summary: DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, DexCom Inc revenues increased 11% to $4.03B. Net income increased 6% to $576.2M. Revenues reflect Distributor segment increase of 11% to $3.43B, Direct segment increase of 14% to $602.9M, United States segment increase of 10% to $2.89B, Outside of United states segment increase of 15% to $1.14B. Net income was partially offset by Selling, general and administrative - Ba increase of 9% to $987.8M